Novavax, Inc. (Nasdaq: NVAX), a US-based global company advancing protein-based vaccines with its Matrix-M adjuvant, announced on Friday that it has named John Trizzino as its new president and chief operating officer.

In the new role, Trizzino will head the commercial; chemistry, manufacturing and controls (CMC), and regulatory functions and will continue to serve on the firm's executive leadership team.

Mr Trizzino has wide range of experience in publicly held companies and more than 25 years in the vaccines market. He has served for 12 years at Novavax, most recently holding the position of executive vice president, chief commercial officer and chief business officer. He has worked as chief executive officer of Immunovaccine and has also held leadership roles at MedImmune, LLC (now AstraZeneca), ID Biomedical and Henry Schein, Inc.